Showing results (341-350 of 734) with videos related to

Sort By:
Pageof 74
The British Journal of Oral & Maxillofacial Surgery|July 19, 2021
Applying the British Association of Oral and Maxillofacial Surgeons quality outcomes metrics to a UK oncology and reconstructive surgery service - benchmarking the dataP Steele, J McMahon, K Dickson, et al.
Leukemia & Lymphoma|February 14, 2015
Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission ratesClive S Zent, Timothy G Call, Deborah A Bowen, et al.
Journal for Immunotherapy of Cancer|July 6, 2021
Expression of KLRG1 and CD127 defines distinct CD8+ subsets that differentially impact patient outcome in follicular lymphomaHongyan Wu, Xinyi Tang, Hyo Jin Kim, et al.
Clinical Lymphoma & Myeloma|May 27, 2008
The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphomaDimitrios Karantanis, Rathan M Subramaniam, Patrick J Peller, et al.
JACC. Case Reports|August 7, 2023
Venoarterial Extracorporeal Membrane Oxygenation After Autologous Stem Cell Transplantation With Pancytopenia: JACC Patient Care PathwaysJames F Howick V, Joshua A Rezkalla, Thomas Tilbury, et al.
Oncotarget|October 6, 2017
Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphomaZhi-Zhang Yang, Hyo Jin Kim, Jose C Villasboas, et al.
Blood Advances|June 10, 2020
ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphomaSteven I Park, Thomas C Shea, Oludamilola Olajide, et al.
Blood Advances|May 1, 2025
Brentuximab Vedotin and Nivolumab for Untreated Patients with Hodgkin Lymphoma: Long-term ResultsBruce David Cheson, Nancy L Bartlett, Betsy Knopf, et al.
Pediatrics|September 1, 1991
Randomized, double-blind trial of deflazacort versus prednisone in juvenile chronic (or rheumatoid) arthritis: a relatively bone-sparing effect of deflazacortJ Loftus, R Allen, R Hesp, et al.
The Lancet. Haematology|October 4, 2020
Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trialBruce D Cheson, Nancy L Bartlett, Betsy LaPlant, et al.
Pageof 74